Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth C Anderson

Showing results (621-630 of 869) with videos related to

Pageof 87
Sort By:
Blood|February 16, 2011
Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implicationsJana Jakubikova, Sophia Adamia, Maria Kost-Alimova, et al.
Blood Advances|January 15, 2025
Nivolumab to restore T-cell fitness in CAR-T refractory multiple myelomaJohannes M Waldschmidt, Noori Sotudeh, Sankalp Arora, et al.
Cancer Cell|November 16, 2005
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from BortezomibDharminder Chauhan, Laurence Catley, Guilan Li, et al.
Blood|August 5, 2004
Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cellsPierfrancesco Tassone, Victor S Goldmacher, Paola Neri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2018
Dual PAK4-NAMPT Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldenström MacroglobulinemiaNa Li, Michael A Lopez, Maria Linares, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 10, 2010
Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myelomaMaría Victoria Mateos, Maria Teresa Cibeira, Paul G Richardson, et al.
Molecular Cancer Research : MCR|April 22, 2020
Polycomb-like Protein 3 Induces Proliferation and Drug Resistance in Multiple Myeloma and Is Regulated by miRNA-15aTengteng Yu, Chenxing Du, Xiaoke Ma, et al.
Blood|February 7, 2009
CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cellsYu-Tzu Tai, Ender Soydan, Weihua Song, et al.
Blood|January 17, 2012
Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector functionYu-Tzu Tai, Holly M Horton, Sun-Young Kong, et al.
Blood|June 16, 2016
Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemiaZachary R Hunter, Lian Xu, Guang Yang, et al.
Pageof 87

Showing results (621-630 of 869) with videos related to

Sort By:
Pageof 87
Blood|February 16, 2011
Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implicationsJana Jakubikova, Sophia Adamia, Maria Kost-Alimova, et al.
Blood Advances|January 15, 2025
Nivolumab to restore T-cell fitness in CAR-T refractory multiple myelomaJohannes M Waldschmidt, Noori Sotudeh, Sankalp Arora, et al.
Cancer Cell|November 16, 2005
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from BortezomibDharminder Chauhan, Laurence Catley, Guilan Li, et al.
Blood|August 5, 2004
Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cellsPierfrancesco Tassone, Victor S Goldmacher, Paola Neri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2018
Dual PAK4-NAMPT Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldenström MacroglobulinemiaNa Li, Michael A Lopez, Maria Linares, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 10, 2010
Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myelomaMaría Victoria Mateos, Maria Teresa Cibeira, Paul G Richardson, et al.
Molecular Cancer Research : MCR|April 22, 2020
Polycomb-like Protein 3 Induces Proliferation and Drug Resistance in Multiple Myeloma and Is Regulated by miRNA-15aTengteng Yu, Chenxing Du, Xiaoke Ma, et al.
Blood|February 7, 2009
CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cellsYu-Tzu Tai, Ender Soydan, Weihua Song, et al.
Blood|January 17, 2012
Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector functionYu-Tzu Tai, Holly M Horton, Sun-Young Kong, et al.
Blood|June 16, 2016
Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemiaZachary R Hunter, Lian Xu, Guang Yang, et al.
Pageof 87